None listed
Conditions
Brief summary
Management of gout focuses on treating the acute attacks and long-term lowering of serum urate so that acute attacks stop. Gout attacks are common when urate lowering treatments are started so treatment with non-steroidal anti-inflammatories, colchicine or steroids are recommended during the first 6 months of urate lowering therapy. However, each of these drugs has potential adverse effects and are contra-indicated in many people with gout. Omega-3 fatty acids are a “natural non-steroidal anti-inflammatory” and may therefore be an appropriate alternative. This study will provide preliminary evidence required to design a full clinical trial of fish oil in gout.
Interventions
Omega-3 oil 2.6gm daily by mouth for six months. Adherence will be monitored by volume of oil returned and by blood omega three fatty acid levels
Sponsors
University of Otago, Christchurch
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Age over 18 years Gout according to the 2015 ACR/EULAR criteria Ability to give informed consent Ability to communicate via telephone Stable dose of allopurinol for at least one month Serum urate >0.36mmol/l at screening
Exclusion criteria
Previous intolerance or allergy with omega-3 fatty acid supplementation Unstable co-morbid health conditions Unable to comply with study procedures Already taking at least 2gm daily of omega-3 supplements Not willing to remain off omega-3 supplements if randomised to control arm Allergy to fish or shell fish Implantable defibrillator Current use of warfarin or dabigatrin
Outcome results
None listed